{"preliminary_commentary":{"by_channel":{"youtube":7,"podcast":3,"x_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04844866\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"DALY 2-EU","nct_id":"NCT04844866","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=daly-2-eu-nct04844866. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"DALY 2-EU","arms":[{"description":"Single infusion of 2.5 × 10\\^6 CAR-transduced autologous T cells per kg/body weight.","label":"Part I: CAR T-cell MB-CART2019.1","type":"EXPERIMENTAL"},{"description":"Single infusion of 2.5 × 10\\^6 CAR-transduced autologous T cells per kg/body weight.","label":"Part II: CAR T-cell MB-CART2019.1","type":"EXPERIMENTAL"},{"description":"R-GemOx R-Pola","label":"PART I: Standard of Care","type":"ACTIVE_COMPARATOR"}],"collaborators":["ICON plc"],"completion_date":{"date":"2031-09-30","type":"ESTIMATED"},"conditions":["Diffuse Large B-cell Lymphoma"],"enrollment":{"count":213,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"MB-CART2019.1","otherNames":["Zamtocabtagene Autoleucel","Zamto-cel"],"type":"GENETIC"},{"name":"Standard of Care","otherNames":["Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab"],"type":"DRUG"}],"last_update":"2026-06-10","lead_sponsor":"Miltenyi Biomedicine GmbH","official_title":"A Pivotal Phase II Randomised, Multi-centre, Open-label Study to Evaluate the Efficacy and Safety of MB-CART2019.1 Compared to SoC Therapy in Participants With r/r DLBCL, Who Are Not Eligible for HDC and ASCT","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2025-01-15","type":"ACTUAL"},"primary_outcomes":[{"measure":"Part I: Event-free survival","timeFrame":"up to 30 weeks after randomisation"},{"measure":"Part II: Best objective response rate","timeFrame":"up to 30 weeks after administration of MB-CART2019.1"}],"references":[],"start_date":{"date":"2021-08-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients","url":"https://clinicaltrials.gov/study/NCT04844866"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/daly-2-eu-nct04844866"}